Post

New research · Ophthalmology
American journal of ophthalmology · 13h
Cohort studyAmerican journal of ophthalmology · 2026

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco, Fangming Jin, Ali G Hamedani, Brian L VanderBeek
Read paper
OphthalmologyCohort study

Nucleic acid synthesis inhibitors/S1P modulators linked to much lower uveitis risk in multiple sclerosis

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco … Brian L VanderBeek
American journal of ophthalmology · 2026
Background

Whether disease-modifying therapies (disease-modifying therapies) for multiple sclerosis alter this risk is unknown.

Purpose

Multiple sclerosis (multiple sclerosis) is associated with an increased risk of noninfectious uveitis (noninfectious uveitis).

Methods

Adults with multiple sclerosis, defined by ≥3 diagnosis codes on separate dates, who received ≥1 disease-modifying therapies prescription and had ≥2 years of prior enrollment.

n = 43,501 patients
Results

risk of new eye inflammation was far lower than with a comparison multiple sclerosis drug

AHR by subgroup · 95% CI
null = 1
nucleic acid synthesis inhibitors/S1P
0.14
fumarates
0.51
anti-CD20
0.66
interferons
0.67
but not natalizumab
0.87
More results

Sensitivity analysis confirmed findings for fumarates (aHR 0.56, 95% CI: 0.38-0.82) and nucleic acid synthesis inhibitors/S1P modulators (aHR 0.16, 95% CI: 0.08-0.33).

“
Conclusion · 1 of 2

Certain disease-modifying therapies classes are associated with a protective effect for noninfectious uveitis in multiple sclerosis.

Conclusion · 2 of 2

If confirmed, these medications could be targeted for personalized multiple sclerosis treatment and potentially repurposed to treat noninfectious uveitis in other patient populations.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving